Stockreport

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Clarus Therapeutics Holdings, Inc.  (CRXT) 
PDF Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% ye [Read more]